Search

Displaying results 1501 - 1510 of 10000 in total
  1. Drug

    Xylometazoline

    go.drugbank.com/drugs/DB06694
    Approved

    Xylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels. … Xylometazoline is an imidazoline derivative [A228523] with sympathomimetic and nasal decongestant activity.

    Mixtures: Ophtrivin A Ophthalmic Dps, nasic - Nasenspray für Kinder 5 mg/500 mgCategories: Adrenergic alpha-1 Receptor Agonists, Heterocyclic Compounds, 1-Ring
  2. Drug

    Valdecoxib

    go.drugbank.com/drugs/DB00580
    ApprovedWithdrawn

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

    Categories: COX-2 Inhibitors, Cytochrome P-450 SubstratesProducts: BEXTRA ® 10 MG TABLETAS RECUBIERTAS, BEXTRA®20 MG TABLETAS RECUBIERTAS
  3. Drug

    Thallous chloride Tl-201

    go.drugbank.com/drugs/DB16624
    Approved

    Synonyms: Thallous chloride Tl 201, Thallous chloride Tl-201Products: Thallous Chloride Tl 201, THALLOUS CHLORIDE Tl 201
  4. Drug

    Trospium

    go.drugbank.com/drugs/DB00209
    ApprovedInvestigational

    Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. … [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211]

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: SPASMEX 30 MG FILM TABLET, 100 ADET, TROSBIO® 30 MG
  5. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed by Lundbeck Seattle Biopharmaceuticals. … [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]

    Products: Vyepti® 100 mg/mL concentrate for solution for infusion, VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML
  6. Drug

    Nicotine

    go.drugbank.com/drugs/DB00184
    ApprovedInvestigational

    It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Cytochrome P-450 SubstratesSynonyms: L(−)-nicotine, (S)-3-(1-methylpyrrolidin-2-yl)pyridine
  7. Drug

    Teriparatide

    go.drugbank.com/drugs/DB06285
    ApprovedInvestigational

    [A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic … Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent.[A251395] It is made up of the first amino(N)-terminal 34 amino acids of the human PTH.

    Synonyms: PTH 1-34, PTH (1-34)Products: MEGAPTH-G Teriparatide 20 micrograms / 80 microliters solution for injection, FORTEO® 250MCG/ML
  8. Drug

    Prednisone

    go.drugbank.com/drugs/DB00635
    ApprovedInvestigationalVet approved

    A synthetic anti-inflammatory glucocorticoid derived from [cortisone].[A187463] It is biologically inert and converted to [prednisolone] in the liver.

    Categories: CHOP-R chemotherapy regimen, P-glycoprotein inducersSynonyms: 1, 2-Dehydrocortisone
  9. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    a treatment for COVID-19. … Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor.

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: JAKAVİ 10 MG TABLET, 168 ADET, JAKAVİ 10 MG TABLET, 56 ADET
  10. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart … [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesProducts: KERENDİA 10 MG FİLM KAPLI TABLET, 98 ADET, KERENDİA 20 MG FİLM KAPLI TABLET, 98 ADET